Moderna Vaccine at Target

FDA refuses review of mRNA flu vaccine

FDA refuses to review Moderna’s mRNA flu vaccine

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA communications and went against the regulator’s established guidance for flu shots.

· 3d

F.D.A. Refuses to Review Moderna Flu Vaccine

· 16h

Moderna remains silent on breakeven target after FDA rejects flu vaccine review

17hon MSN

Moderna reiterates 10% revenue-growth target as Covid vaccine demand falls

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% ...

16h

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...

Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results